Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SynAct Pharma AB ( (SE:SYNACT) ) has shared an update.
SynAct Pharma AB announced its participation in the Nordic Life Science Days 2025, a significant event for engaging with potential partners and investors. The company will discuss its lead program, resomelagon, which is in Phase 2b development for autoimmune diseases and hyperinflammatory responses in viral infections. The event provides an opportunity for SynAct to advance discussions on its innovative resolution therapy approach, particularly in rheumatoid arthritis, and strengthen its industry positioning.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, helping patients achieve immune balance.
Average Trading Volume: 175,390
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.06B
For a thorough assessment of SYNACT stock, go to TipRanks’ Stock Analysis page.